Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H, Nakano Y, Morinaga T, Hashimoto-Tamaoki T. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol 2006; 12(36): 5884-5889
Corresponding Author of This Article
Reigetsu Yoshikawa, MD, PhD, Second Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. firstname.lastname@example.org
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Reigetsu Yoshikawa, Hidenori Yanagi, Yoshinori Fujiwara, Masafumi Noda, Toshihiko Yagyu, Makoto Gega, Tsutomu Oshima, Yoshinori Fujiwara, Takehira Yamamura, Second Department of Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
Reigetsu Yoshikawa, Haruki Okamura, Tomoko Hashimoto-Tamaoki, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
Chun-Shen Shen, Department of Dermatology, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
Yoshiro Nakano, Tomonori Morinaga, Tomoko Hashimoto-Tamaoki, Department of Genetics, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
Author contributions: All authors contributed equally to the work.
Supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, grant No. 16591374, and by Grant-in-Aid for Researchers, Hyogo College of Medicine
Correspondence to: Reigetsu Yoshikawa, MD, PhD, Second Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. email@example.com
Telephone: +81-798-456372 Fax: +81-798-456373
Received: June 7, 2006 Revised: August 10, 2006 Accepted: August 17, 2006 Published online: September 28, 2006
AIM: To investigate the possible role of polysaccharide-K (PSK) -related markers in predicting distant metastasis and in the clinical outcome of colorectal cancer (CRC).
METHODS: Firstly, we used protein microarrays to analyze the in vitro expression profiles of potential PSK-related markers in the human colorectal adenocarcinoma cell line SW480, which carries a mutant p53 gene. Then, we investigated the clinical implications of these markers in the prognosis of CRC patients.
RESULTS: ECA39, a direct target of c-Myc, was identified as a candidate protein affected by the anti-metastatic effects of PSK. Immunohistochemistry revealed that ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases compared to those without (P < 0.00001). Positive ECA39 expression was shown to be highly reliable for the prediction of distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, negative predictive value: 90%). A significantly higher cumulative 5-yr disease free survival rate was observed in the ECA39-negative patient group (77.3%) compared with the ECA39-positive patient group (25.8%) (P < 0.05).
CONCLUSION: Our results suggest that ECA39 is a dominant predictive factor for distant metastasis in patients with advanced CRC and that its suppression by PSK might represent a useful application of immunotherapy as part of a program of integrated medicine.
Citation: Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H, Nakano Y, Morinaga T, Hashimoto-Tamaoki T. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol 2006; 12(36): 5884-5889
Colorectal cancer (CRC) is one of the three most frequent malignancies in Western countries. CRC patient survival rates are delineated by local recurrence and lymphatic and hematogenous dissemination[1,2] and, once metastatic disease is diagnosed, the 5-year survival rate is less than 5%. In the majority of cases, chemotherapy is the recommended treatment for patients with advanced metastatic disease. Recently, we have achieved good clinical results in the treatment of CRC using ‘Pharmacokinetic Modulating Chemotherapy (PMC)’, which was designed as a hybrid of lower metronomic and higher shorter plasma 5-FU concentration. The cumulative 5-year survival rate of Dukes’ C CRC patients was 95% in the group treated with PMC, compared with 67% in the non-PMC group (P = 0.003)[3,4]. Our PMC regimen also significantly decreased liver metastasis, resulting in a median liver metastasis-free time after hepatectomy of 34.2 mo in the PMC group compared with 18.4 mo in the non-PMC group (P = 0.00002). PMC offers the advantages of reduced toxicity and lower costs through outpatient treatment. However, the prognosis of some patients remains poor despite vigorous anti-cancer therapy. Extrahepatic recurrence, mostly in the lung, cannot always be reduced by PMC alone, although PMC turned out well for the risk reduction of liver metastasis. Indeed, intensive chemotherapy has been shown to cause a comparatively higher risk of extrahepatic distant metastases such as the lung, bone, brain and peritoneum, with an overall recurrence rate in CRC patients receiving PMC of 13.1%. While chemotherapy with hepatic arterial infusion or second-look liver resection can control the prognosis of liver metastasis to some extent, extrahepatic recurrence is refractory to any known treatment. The management of extrahepatic recurrence is a major problem as the prognosis of patients suffering extrahepatic recurrence is significantly worse (mean survival of 2 mo from diagnosis) compared with those with liver metastasis alone (mean survival of 26 mo from diagnosis) (P < 0.05).
The integration of immunopotentiating agents with the extant treatment regimens of surgery, chemotherapy, and radiation therapy has gained popularity as an adjuvant therapy for cancer during the last three decades. The use of complementary and alternative medicine (CAM) is a growing field in health care, particularly among cancer patients in the advanced stages of disease. However, recent reports have shown that while expenditure on CAM is high, 44.6%-66.7% of cancer patients receiving palliative care use CAM without sufficient information[7,8].
Polysaccharide-K (PSK), or Krestin, is a protein-bound polysaccharide biological response modifier prepared from the mushroom Coriolus versicolor, that has been used in traditional Chinese medicine for centuries. PSK is widely used in adjuvant therapy after surgery or radiotherapy in Japan and other Asian countries, and the Japanese National Health Insurance scheme covers the use of PSK for gastric, colorectal, and lung cancers. Randomized, controlled clinical studies have revealed that the use of PSK in adjuvant therapy for gastric, colorectal, esophageal, and lung cancers significantly extends the 5-year survival rates of patients by 10% to 20%[9-12]. Compared with CRC patients who did not receive PSK, PSK-treated patients showed a higher 5-year survival rate (73.0% in PSK group vs 58.8% in non-PSK group in stage II or III, and 60.0% vs 32.1% in stage III only) and lower rates of local recurrence (OR 0.74) and systemic recurrence (OR 0.52); lung metastases (OR 0.27), lymph node recurrence (OR 0.16), and peritoneal dissemination (OR 0.86). Based on the findings of these studies, we have been administering PSK to patients with advanced CRC since 2001. Compatible with the findings of Ohwada et al, we have observed that extrahepatic recurrences are significantly decreased when PSK therapy is used in combination with the standard PMC regimen (manuscript in preparation).
PSK produces very few adverse side effects, and its characteristics allow long-term oral administration. In vitro studies have confirmed that PSK induces the expression of several cytokine genes including TNF-α, IL-1, IL-1R, IL-2, IL-4, IL-6, IL-7, and IL-8[12-15]. Anti-neoplastic effects of PSK have also been reported in animal models, and involve the radical trapping and modulation of cytokine production and effector cell functions[16,17]. Recently, we have shown that PSK may have an additional anti-tumor effect on the cancer cells per se without disturbing cell-cycle progression. PSK might also alter the local characteristics of tissue-specific factors as well as their host-mediated activities.
We hypothesized that some PSK-related markers could be influential in predicting the occurrence of distant metastasis in CRC patients. In order to identify those molecular markers associated with the transition from primary CRC to distant metastases, we used a protein array containing 500 human antibodies in the human colorectal adenocarcinoma cell line SW480 to screen for alterations in protein expression that are potentially required for the direct action of PSK. SW480 carries a mutant p53 gene; such mutations have been found in approximately half of all colorectal cancers and are associated with lymphatic dissemination and poor prognosis[19,20]. We examined the expressions of candidate marker proteins in cancerous tissue obtained from CRC patients and accordingly assessed their usefulness as prognostic markers for distant metastasis.
MATERIALS AND METHODS
Cell culture and PSK treatment
The colorectal adenocarcinoma cell line, SW480, carrying a mutant p53 gene was obtained from the Human Science Research Resource Bank (Tokyo, Japan). Cells were grown in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 100 mL/L fetal bovine serum (FBS; HyClone, Logan, UT, USA), 2 mmol/L glutamine, 100 000 U/L penicillin, 100 mg/L streptomycin, and 40 mg/L gentamycin at 37°C in a humidified atmosphere of 50 mL/L CO2. For the cell growth study, 106 cells were plated per 60-mm dish and treated with various concentrations of PSK (Kureha Chemical Co., Tokyo, Japan). Cells were counted using a hemocytometer on the days indicated. Then they were prepared for protein extraction and Ab arrays (Clontech, Palo Alto, CA, USA).
Identification of protein expression profiles by antibody microarray
Extraction of whole cellular protein, microarray hybridisation, scanning, grid-assisted spot identification, and analysis were performed according to the manufacturer’s instructions (Clontech). Briefly, 25 μg whole cellular protein was extracted, labelled with the same volume of Cy3 and Cy5, hybridized with Antibody (Ab) Microarray, and the level of radioactivity was measured by scintillation counting. Sample and control-labelled probes were mixed together and hybridized to Ab Microarray slides containing 500 human antibodies in the Ab Microarray (No. 3080600). The names of these proteins are available at http://www.clontech.com/clontech/products/families/abarray/nanoscale.shtml . Hybridized slides were scanned and the scanner output images were analyzed using AtlasImageTM software, following localization by the overlaying of a grid on the fluorescent images. Fluorescent signal intensities were normalized by the Ab Microarray Analysis Workbook. Both final reported intensities were filtered, and those spots with intensities less than 0.75 or more than 1.32 were eliminated. The results were obtained from two independent experiments.
Sixty-three patients (31 women and 32 men) with a mean age of 60 years (range 37-83 years) and with surgically excised Dukes’ C lower rectal carcinomas beneath the peritoneal reflexion were studied in the Hyogo College of Medicine between April 1986 and March 1995. Thirty-five of these patients (12 women and 23 men) with a mean age of 62.9 years (range 41-83 years) were enrolled in this study. The histological grades of carcinomas are as follows: 6 were well differentiated, 27 were moderately differentiated, and 2 were poorly differentiated or mucinous carcinomas. Follow-up information was obtained from office charts and hospital records. All patients were followed up for 60 mo after the initial operation. Local recurrence was defined as any tumor recurrence within the pelvis or anal canal. Distant recurrence was defined as any tumor recurrence outside the pelvis and included metastasis to the liver, lung, bone or the abdominal cavity. No recurrence was observed in 22 patients, distant recurrence was observed in 13 (3 cases of recurrence in the lymph nodes, 3 in the liver and 7 in the lungs), and local recurrence in 2 patients. The Ethics Committee of the Institution approved the study protocol.
CRC tissue specimens were processed using conventional procedures for paraffin embedding, cut into 4-μm sections, and mounted onto poly-l-lysine-coated slides. Sections were dewaxed in xylene, rehydrated in a descending alcohol series, heated twice in a microwave oven for 5 min for antigen retrieval, blocked for endogenous peroxidase activity with 30 mL/L H2O2 in methanol, and then blocked for non-specific antibody binding with normal rabbit serum. They were incubated overnight at 4°C with a mouse monoclonal Ab against human ECA39 (BD Biosciences Pharmingen, San Jose, CA, USA) followed by treatment with a standard avidin-biotin-peroxidase complex. The slides were developed with 3, 3-diaminobenzidine tetrahydrochloride solution containing 1 mL/L H2O2 and were lightly counterstained with hematoxylin. Normal mouse IgG was substituted for the primary antibody as a negative control. The sections were examined microscopically by three of the authors (Y.F., R.Y., and T.H-T.) without knowledge of their clinicopathologic features. ECA39 expression was categorized according to staining intensity compared with interstitial infiltrates as follows: score 3 (strong), staining intensity more than interstitial infiltrates; score 2 (moderate), staining intensity equal to interstitial infiltrates; score 1 (mild), staining intensity less than interstitial infiltrates; and score 0 (negative), no staining. We then categorized ECA39 expression according to ECA39 expression scores: score 1 to 3, ECA39 positive; score 0, ECA39 negative.
Disease-free survival (DFS) and overall survival (OS) curves were generated by the Kaplan-Meier method, and the Cox-Mantel test was used to compare the curves. Death without recurrence was excluded from the analysis. Values of P < 0.05 were considered statistically significant. Statistical analyses were carried out using STATISTICA statistical software, version 06J (STATISTICA, Tulsa, OK, USA).
Suppression of cell growth by PSK
The effects of various concentrations of PSK (0 to 1000 mg/L) on the growth of SW480 cells was examined 96 h after treatment, and exposure to 10, 100, 500 and 1000 mg/L PSK was shown to suppress growth by 92.1%, 83.6%, 69.5% and 60.8%, respectively. Each figure represents the mean of more than three independent experiments.
Analysis of expression profiles
Protein expression in SW480 cells was analyzed following 24 h treatment with 500 mg/L PSK using an Ab Microarray (No. 3080600). Under basic selection conditions, a total of 10 proteins were selected from the 500 human proteins available on the array slide. These proteins were identified on the basis of their altered expression following exposure to PSK, with 1.32-fold or higher ratios, and included 5 upregulated and 5 downregulated proteins (Table 1). Proteins showing upregulated expression, in the order of decreasing ratio, are HDJ-2, TNIK, TRAX, C-NAP1, and Moesin. Proteins showing downregulation, in the order of increasing ratio, are ECA39, Caspase-9/ICE-LAP6/Apaf-3, Synaptotagmin, ERK2 (MAPK2), and PMCA2.
Table 1 Differential protein expression in SW480 cell line following exposure to PSK, defined by a 1.32-fold or greater change.
Normalized average INR
Correlation of ECA39 expression with CRC patient prognosis
ECA39 was selected from these 10 candidate proteins as a distant metastasis-related marker in CRC after immunohistochemical analysis of CRC tissue specimens (Figure 1). ECA39 was expressed at significantly higher levels in tumor tissues with distant metastases (13 of 15 expressed positive ECA39) compared to those without metastases (2 of 20 expressed positive ECA39, P < 0.00001). Positive ECA39 expression was also shown to be highly reliable in predicting distant metastases (sensitivity: 86.7%, specificity: 90%, positive predictive value: 86.7%, and negative predictive value: 90%). Kaplan-Meier analysis revealed a significant decrease in DFS of patients with positive ECA39 expression (25.8%) compared with patients with negative ECA39 expression (77.3%) (P = 0.034; Figure 2). The 5-year OS rate of ECA39-positive patients was 53.0%, compared with 83.3% for ECA39-negative patients, although this difference was not statistically significant (P = 0.055; Figure 3).
Figure 1 Immunohistochemical detection of ECA39 in rectal cancers (A: × 40; B: × 100.
Bars indicate 100 μm).
Figure 2 Five-year disease-free survival curves for eligible patients with pathologic stage III cancer in the ECA39-negative group and ECA39-positive group.
Figure 3 Five-year overall survival curves for eligible patients with pathologic stage III cancer in the ECA39-negative group and ECA39-positive group.
Normal cells undergo certain changes during their transformation into invasive malignant clones with metastatic potential. Molecular determinants occurring during the development of sporadic CRC include mutations in certain tumor suppressor genes (APC, DCC, Smad-2, Smad-4, p53) and oncogenes (K-ras) that have been summarized in the adenoma-carcinoma sequence initially proposed by Fearon and Vogelstein. However, because only 8% of CRC harbor concomitant mutations of APC, K-ras, and p53, it seems likely that additional pathogenic alterations are instrumental in the mediation of the progression and metastasis of CRC. Cellular transformation provokes tissue remodeling inside neoplastic lesions and in the periphery of the tumor. Disorders in the local characteristics of tissue-specific factors play an essential role in cancer progression. In the present study, we have demonstrated that the ECA39 expression, which can be suppressed by PSK, has the potential to predict distant metastasis.
The ECA39 protein was originally identified by the overexpression of its mRNA in an undifferentiated mouse teratocarcinoma cell line. The ECA39 gene harbors a functional c-Myc binding sequence located 3’ of its transcription initiation site, and has been shown to be a direct target for c-Myc activity in both mice and humans[24,25]. The functional implications of individual c-Myc target genes including ornithine decarboxylase[26,27], p53, and cdc25A, are now complemented by large surveys of the c-Myc network as a therapeutic target in cancer. The c-myc oncogene is essential for cell proliferation but, paradoxically, also promotes cell death. The biological rationale for this dual signal is that c-Myc intrinsically regulates malignant transformation. ECA39 shares significant homology with the prokaryotic protein branched-chain amino acid aminotransferase (BCAT), and is highly expressed during the log phase and is down-regulated during the stationary phase of growth. Thus, ECA39 might be involved in the regulation of the cell cycle. Disruption of the ECA39 gene results in an increased growth rate in comparison to wild type. As shown in the present study, ECA39 is a highly reliable marker in the prediction of distant metastasis and, in combination with other biomarkers, might produce an even higher predictability of poor prognosis. Despite significant progress in the identification of markers predicting CRC patient prognosis, there remains a need for clinical predictors of distant metastasis in order to strengthen patient surveillance. This would allow the tailoring of treatment to individual patients and the application of evidence-oriented integrated medicine, thus maximizing the probability of optimal response to the therapy.
Previous reports have demonstrated that c-Myc acts as a biomarker in the prediction of patient response to treatment with 5-FU and camptothesin[32,33]. Evidence of ECA39-based administration of PSK could also favor some CRC patients by sensitizing their response to chemotherapy, protecting normal cells during treatment as well as having an anti-metastatic effect. Such possibilities need to be confirmed in larger clinical studies, which are warranted both in Japan and world-wide. We believe that the acquisition of knowledge of integrated medicine by physicians, especially oncologists, is essential and should not be underestimated. Moreover, oncologists should discuss the role of integrated medicine with their patients and encourage patients to participate in well-organized research on integrated approaches to therapy.
Here, we identified ECA39 as a biomarker that predicts distant metastasis in CRC patients. ECA39 is thought to play a role in metastasis, and could represent a potential diagnostic, prognostic, or even therapeutic target. Furthermore, the metastasis-tumor associated ECA39 profile could be of use in the selection process of tumors that are likely to develop metastases, thus optimizing the application of immunotherapy by PSK and improving clinical outcome.
The authors are grateful to Mr Matsuda N for his technical assistance.
S- Editor Wang GP L- Editor Zhu LH E- Editor Bi L
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003;95:1276-1299.
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000.CA Cancer J Clin. 2000;50:7-33.
Yanagi H, Noda M. Yoshikawa R, Ikeuchi H, Gega M, Yamamura T, Kusunoki M. Randomized clinical trial of pharmacokinetic modulating chemotherapy (PMC) in combination with continuous 5-FU infusion plus oral UFT for adjuvant chemotherapy after curative resection for Dukes' C colorectal cancer patients.Proc Am Soc Clin Oncol. 2003;22:293.
Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.Cancer Res. 2001;61:1029-1037.
Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.Cancer. 2000;89:1228-1235.
Gega M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Postoperative follow-up of tumor markers once a month is beneficial to the colorectal cancer patients with pharmacokinetic modulating chemotherapy treatment.Proc Am Soc Clin Oncol. 2003;22:329.
Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions.J Clin Oncol. 2000;18:2515-2521.
Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan.J Clin Oncol. 2005;23:2645-2654.
Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.Lancet. 1994;343:1122-1126.
Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.Br J Cancer. 2004;90:1003-1010.
Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan.Am J Clin Oncol. 1995;18:216-222.
Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, Kawashima M, Niibe H. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients.Cancer Detect Prev. 1997;21:71-77.
Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells.Lymphokine Res. 1990;9:475-483.
Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S, Tobe T. In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer.Cancer Immunol Immunother. 1991;32:335-341.
Noguchi K, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Tani M, Mizobata S, Hotta T, Arii K, Tamai M. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.Anticancer Res. 1995;15:255-258.
Ehrke MJ, Reino JM, Eppolito C, Mihich E. The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens.Int J Immunopharmacol. 1983;5:35-42.
Hosokawa M, Mizukoshi T, Morikawa K, Xu ZY, Kobayashi H. The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites.Cancer Immunol Immunother. 1986;22:181-185.
Yoshikawa R, Yanagi H, Hashimoto-Tamaoki T, Morinaga T, Nakano Y, Noda M, Fujiwara Y, Okamura H, Yamamura T. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells.Oncol Rep. 2004;12:1287-1293.
Goh HS, Chan CS, Khine K, Smith DR. p53 and behaviour of colorectal cancer.Lancet. 1994;344:233-234.
Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer.Gastroenterology. 1994;106:42-48.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis.Cell. 1990;61:759-767.
Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.Proc Natl Acad Sci USA. 2002;99:9433-9438.
Niwa O, Kumazaki T, Tsukiyama T, Soma G, Miyajima N, Yokoro K. A cDNA clone overexpressed and amplified in a mouse teratocarcinoma line.Nucleic Acids Res. 1990;18:6709.
Benvenisty N, Leder A, Kuo A, Leder P. An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence.Genes Dev. 1992;6:2513-2523.
Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast.Proc Natl Acad Sci U S A. 1996;93:7143-7148.
Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc.Proc Natl Acad Sci U S A. 1993;90:7804-7808.
Wagner AJ, Meyers C, Laimins LA, Hay N. c-Myc induces the expression and activity of ornithine decarboxylase.Cell Growth Differ. 1993;4:879-883.
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.Cell Growth Differ. 1993;4:57-65.
Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc.Nature. 1996;382:511-517.
Prochownik EV. c-Myc as a therapeutic target in cancer.Expert Rev Anticancer Ther. 2004;4:289-302.
Eden A, Simchen G, Benvenisty N. Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases.J Biol Chem. 1996;271:20242-20245.
O’Dwyer PJ, Stevenson JP. Chemotherapy of advanced colorectal cancer.Gastrointestinal Oncology, Cancer Treatment and Research. Norwell: Kluwer Academic Publishers; 1998;111-152.
Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, Aranes MJ, Augenlicht LH. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis.Br J Cancer. 2003;89:1757-1765.